Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) has received an approval letter from the FDA for its abbreviated new drug application for its sevelamer carbonate tablets, a Monday bourse filing said.
The tablets are used to control hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis.
Hong Kong- and China-listed shares of the pharmaceutical company closed 2% higher on Monday.
Price (HKD): $6.21, Change: $+0.12, Percent Change: +1.97%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments